Study of Pembrolizumab and M032 (NSC 733972)

Must have received: external beam radiotherapy — brain

Patients must have failed external beam radio-therapy to the brain

Must have received: temozolomide (temozolomide)

if eligible and tolerated, undergone appropriate treatment with temozolomide chemotherapy

Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy

Has received prior therapy with an anti-PD-1, anti-PD-L1, or antiPDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137)

Cannot have received: systemic anti-cancer therapy

Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation

Cannot have received: live vaccine

Has received a live vaccine within 30 days prior to the first dose of study drug

Cannot have received: investigational agent or device

Is currently participating in or has participated in a study of an interventionally-directed investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment

Cannot have received: experimental viral therapy or gene therapy

have received experimental viral therapy or gene therapy at any time (e.g., adenovirus, retrovirus or herpes virus protocol)

Cannot have received: Gliadel Therapy (Gliadel)

Receipt of Gliadel Therapy

Cannot have received: Bevacizumab (Bevacizumab)

Exception: Receipt of Bevacizumab (Avastin) greater than 4 weeks of scheduled M032 administration does not exclude patient

Receipt of Bevacizumab (Avastin) therapy within 4 weeks of scheduled M032 administration